The use of SGLT2 inhibitors has been a game-changer in the treatment of heart failure (HF). Now, another drug class has ...

The US regulator has cleared use of Kerendia (finerenone) for the treatment of heart failure patients who have a left ...

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

Approval of Kerendia was based on results from the Phase III FINEARTS-HF trial, which demonstrated statistically significant ...

Bayer AG BAYRY announced that the FDA has approved a label expansion of kidney disease drug Kerendia (finerenone). The ...

Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...

Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic ...

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

The going has been good for the German pharmaceutical giant Bayer BAYRY this year. Shares have surged 62.9% year to date ...

In 2023, Bayer reported €270 million in sales for Kerendia, a 152% increase over its sales in 2022. Bayer has touted the once-daily pill’s blockbuster potential as a treatment for both kidney ...

Bayer AG said the drug Kerendia has shown potential to significantly reduce sudden cardiac death among patients with chronic kidney disease and diabetes, a boost to its potential as a blockbuster ...

Bayer will present new cardiovascular (CV) and renal subgroup analyses for KERENDIA® (finerenone) from the comprehensive clinical trial program, inclu.